Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94

1.

The nuclear membrane organization of leukotriene synthesis.

Mandal AK, Jones PB, Bair AM, Christmas P, Miller D, Yamin TT, Wisniewski D, Menke J, Evans JF, Hyman BT, Bacskai B, Chen M, Lee DM, Nikolic B, Soberman RJ.

Proc Natl Acad Sci U S A. 2008 Dec 23;105(51):20434-9. doi: 10.1073/pnas.0808211106.

2.

The nuclear membrane leukotriene synthetic complex is a signal integrator and transducer.

Bair AM, Turman MV, Vaine CA, Panettieri RA Jr, Soberman RJ.

Mol Biol Cell. 2012 Nov;23(22):4456-64. doi: 10.1091/mbc.E12-06-0489.

3.

Colocalization of cytosolic phospholipase A2, 5-lipoxygenase, and 5-lipoxygenase-activating protein at the nuclear membrane of A23187-stimulated human neutrophils.

Pouliot M, McDonald PP, Krump E, Mancini JA, McColl SR, Weech PK, Borgeat P.

Eur J Biochem. 1996 May 15;238(1):250-8.

4.

5-lipoxygenase-activating protein stimulates the utilization of arachidonic acid by 5-lipoxygenase.

Abramovitz M, Wong E, Cox ME, Richardson CD, Li C, Vickers PJ.

Eur J Biochem. 1993 Jul 1;215(1):105-11.

5.

5-lipoxygenase and 5-lipoxygenase-activating protein are localized in the nuclear envelope of activated human leukocytes.

Woods JW, Evans JF, Ethier D, Scott S, Vickers PJ, Hearn L, Heibein JA, Charleson S, Singer II.

J Exp Med. 1993 Dec 1;178(6):1935-46.

6.

Regulation of the activity of 5-lipoxygenase, a key enzyme in leukotriene biosynthesis.

Rådmark O, Samuelsson B.

Biochem Biophys Res Commun. 2010 May 21;396(1):105-10. doi: 10.1016/j.bbrc.2010.02.173. Review.

PMID:
20494120
7.

Requirement of a 5-lipoxygenase-activating protein for leukotriene synthesis.

Dixon RA, Diehl RE, Opas E, Rands E, Vickers PJ, Evans JF, Gillard JW, Miller DK.

Nature. 1990 Jan 18;343(6255):282-4.

PMID:
2300173
8.

FLAP: a novel drug target for inhibiting the synthesis of leukotrienes.

Ford-Hutchinson AW.

Trends Pharmacol Sci. 1991 Feb;12(2):68-70.

PMID:
2024291
9.

Regulation of the biosynthesis of the sulphido-leukotrienes.

Ford-Hutchinson AW.

Adv Exp Med Biol. 1997;400B:841-7. Review. No abstract available.

PMID:
9547637
10.
11.

Lipid bodies in oxidized LDL-induced foam cells are leukotriene-synthesizing organelles: a MCP-1/CCL2 regulated phenomenon.

Silva AR, Pacheco P, Vieira-de-Abreu A, Maya-Monteiro CM, D'Alegria B, Magalhães KG, de Assis EF, Bandeira-Melo C, Castro-Faria-Neto HC, Bozza PT.

Biochim Biophys Acta. 2009 Nov;1791(11):1066-75. doi: 10.1016/j.bbalip.2009.06.004.

PMID:
19573621
12.

The novel benzimidazole derivative BRP-7 inhibits leukotriene biosynthesis in vitro and in vivo by targeting 5-lipoxygenase-activating protein (FLAP).

Pergola C, Gerstmeier J, Mönch B, Çalışkan B, Luderer S, Weinigel C, Barz D, Maczewsky J, Pace S, Rossi A, Sautebin L, Banoglu E, Werz O.

Br J Pharmacol. 2014 Jun;171(12):3051-64. doi: 10.1111/bph.12625.

13.

5-lipoxygenase and FLAP.

Peters-Golden M, Brock TG.

Prostaglandins Leukot Essent Fatty Acids. 2003 Aug-Sep;69(2-3):99-109. Review.

PMID:
12895592
14.

A23187-induced translocation of 5-lipoxygenase in osteosarcoma cells.

Kargman S, Vickers PJ, Evans JF.

J Cell Biol. 1992 Dec;119(6):1701-9.

16.
17.

Inhibition of leukotriene biosynthesis.

Ford-Hutchinson AW.

Ann N Y Acad Sci. 1991;629:133-42. Review. No abstract available.

PMID:
1952545
18.

5-Lipoxygenase.

Ford-Hutchinson AW, Gresser M, Young RN.

Annu Rev Biochem. 1994;63:383-417. Review. No abstract available.

PMID:
7979243
19.

The effect of 5-lipoxygenase-activating protein (FLAP) on substrate utilization by 5-lipoxygenase.

Vickers PJ, Deluca C, Wong E, Abramovitz M.

Adv Exp Med Biol. 1997;400A:145-51. No abstract available.

PMID:
9547550
20.

Crystal structure of inhibitor-bound human 5-lipoxygenase-activating protein.

Ferguson AD, McKeever BM, Xu S, Wisniewski D, Miller DK, Yamin TT, Spencer RH, Chu L, Ujjainwalla F, Cunningham BR, Evans JF, Becker JW.

Science. 2007 Jul 27;317(5837):510-2.

Items per page

Supplemental Content

Support Center